Health Tech Nerds Radio

With Rae out at HLTH, it’s just Kevin and Martin this week, and it’s a very consumer-heavy episode. They start with Oura’s $625M all-cash acquisition of Counsel Health, weeks after Oura pulled its IPO. Kevin argues the roadshow already told us Oura sees itself as a healthcare company, not a hardware maker, and that its real edge is a customer base that skews female and wealthy.

From there it’s Hims and Ro. Hims lost about 100,000 subscribers after pulling back on marketing, saw gross margin slide, and is paying Andrew Huberman close to $10M a year as it bets on peptides. Ro, meanwhile, is telling a “zombie to refounding” story on its way to $2B in revenue, which raises the question of whether either company is a durable brand or just a middleman for Lilly and Novo.

Martin then unpacks CMS’s hold harmless period for Medicaid work requirements and why the rollout could get messy. They close with Spark’s AEP data, the Surgery Partners bidding war, and CMS’s Superintelligence roadmap.

For more from Health Tech Nerds, subscribe to our weekly newsletters: https://www.healthtechnerds.com/subscribe

What is Health Tech Nerds Radio?

Where we share our weekly news debriefs and discussions with industry experts. These are lo-fi recordings aimed at giving our readers more opportunities to engage with our analysis and a view into some of the conversations that shape it.